Clinical Trial: Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292441) titled 'Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss' on Nov. 20.

Brief Summary: This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight.

In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.

St...